Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H15N7O2S3 |
Molecular Weight | 337.445 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1
InChI
InChIKey=XUFQPHANEAPEMJ-UHFFFAOYSA-N
InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)
Molecular Formula | C8H15N7O2S3 |
Molecular Weight | 337.445 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00927Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/famotidine.html
Sources: http://www.drugbank.ca/drugs/DB00927
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/famotidine.html
Famotidine, a competitive histamine H2-receptor antagonist, is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Famotidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Famotidine include an increase in gastric bacterial flora such as nitrate-reducing organisms. Famotidine binds competitively to H2-receptors located on the basolateral membrane of the parietal cell, blocking histamine affects. This competitive inhibition results in reduced basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8204567
Curator's Comment: Famotidine is a potent highly selective H2 receptor antagonist which crosses the blood-brain barrier.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1941 Sources: http://www.drugbank.ca/drugs/DB00927 |
0.3 µM [IC50] | ||
Target ID: CHEMBL2073673 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16141367 |
6.7 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | PEPCID Approved UsePEPCID is indicated in:
1. Short-term treatment of active duodenal ulcer.
2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer.
3. Short-term treatment of active benign gastric ulcer.
4. Short-term treatment of gastroesophageal reflux disease (GERD). PEPCID is indicated for shortterm
treatment of patients with symptoms of GERD
PEPCID is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy
5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple
endocrine adenomas) Launch Date5.29632002E11 |
|||
Curative | PEPCID Approved UsePEPCID is indicated in:
1. Short-term treatment of active duodenal ulcer.
2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer.
3. Short-term treatment of active benign gastric ulcer.
4. Short-term treatment of gastroesophageal reflux disease (GERD). PEPCID is indicated for shortterm
treatment of patients with symptoms of GERD
PEPCID is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy
5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple
endocrine adenomas) Launch Date5.29632002E11 |
|||
Primary | PEPCID Approved UsePEPCID is indicated in:
1. Short-term treatment of active duodenal ulcer.
2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer.
3. Short-term treatment of active benign gastric ulcer.
4. Short-term treatment of gastroesophageal reflux disease (GERD). PEPCID is indicated for shortterm
treatment of patients with symptoms of GERD
PEPCID is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy
5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple
endocrine adenomas) Launch Date5.29632002E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
73 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAMOTIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
424 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAMOTIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAMOTIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
82.5% |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAMOTIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.5 mg/kg 2 times / day steady, oral Recommended Dose: 0.5 mg/kg, 2 times / day Route: oral Route: steady Dose: 0.5 mg/kg, 2 times / day Sources: |
unhealthy, 11 - 15 years n = 8 Health Status: unhealthy Condition: gastric or duodenal ulcers Age Group: 11 - 15 years Sex: M Population Size: 8 Sources: |
|
80 mg 3 times / day steady, oral Highest studied dose Dose: 80 mg, 3 times / day Route: oral Route: steady Dose: 80 mg, 3 times / day Sources: |
unhealthy, 20 - 70 years n = 10 Health Status: unhealthy Condition: COVID-19 Age Group: 20 - 70 years Sex: M+F Population Size: 10 Sources: |
Other AEs: Dizziness, Dry skin... Other AEs: Dizziness (grade 1, 2 patients) Sources: Dry skin (grade 1, 1 patient) Insomnia (grade 1, 1 patient) Gastrointestinal disorder (NOS) (grade 1, 1 patient) Forgetfulness (grade 1, 1 patient) |
1 mg/kg 1 times / day steady, intravenous Recommended Dose: 1 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 1 mg/kg, 1 times / day Sources: |
unhealthy, 6 - 15 years n = 6 Health Status: unhealthy Condition: gastric or duodenal ulcers Age Group: 6 - 15 years Sex: M Population Size: 6 Sources: |
|
26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Other AEs: Anemia, Nausea... Other AEs: Anemia (2 patients) Sources: Nausea (6 patients) Dyspepsia (5 patients) Diarrhea (5 patients) Constipation (4 patients) Abdominal pain upper (3 patients) Gastroesophageal reflux disease (2 patients) Vomiting (2 patients) Stomach discomfort (2 patients) Abdominal pain (2 patients) Edema peripheral (2 patients) Arthralgia (1 patient) Back pain (2 patients) Headache (3 patients) Hypertension (3 patients) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Dry skin | grade 1, 1 patient | 80 mg 3 times / day steady, oral Highest studied dose Dose: 80 mg, 3 times / day Route: oral Route: steady Dose: 80 mg, 3 times / day Sources: |
unhealthy, 20 - 70 years n = 10 Health Status: unhealthy Condition: COVID-19 Age Group: 20 - 70 years Sex: M+F Population Size: 10 Sources: |
Forgetfulness | grade 1, 1 patient | 80 mg 3 times / day steady, oral Highest studied dose Dose: 80 mg, 3 times / day Route: oral Route: steady Dose: 80 mg, 3 times / day Sources: |
unhealthy, 20 - 70 years n = 10 Health Status: unhealthy Condition: COVID-19 Age Group: 20 - 70 years Sex: M+F Population Size: 10 Sources: |
Gastrointestinal disorder (NOS) | grade 1, 1 patient | 80 mg 3 times / day steady, oral Highest studied dose Dose: 80 mg, 3 times / day Route: oral Route: steady Dose: 80 mg, 3 times / day Sources: |
unhealthy, 20 - 70 years n = 10 Health Status: unhealthy Condition: COVID-19 Age Group: 20 - 70 years Sex: M+F Population Size: 10 Sources: |
Insomnia | grade 1, 1 patient | 80 mg 3 times / day steady, oral Highest studied dose Dose: 80 mg, 3 times / day Route: oral Route: steady Dose: 80 mg, 3 times / day Sources: |
unhealthy, 20 - 70 years n = 10 Health Status: unhealthy Condition: COVID-19 Age Group: 20 - 70 years Sex: M+F Population Size: 10 Sources: |
Dizziness | grade 1, 2 patients | 80 mg 3 times / day steady, oral Highest studied dose Dose: 80 mg, 3 times / day Route: oral Route: steady Dose: 80 mg, 3 times / day Sources: |
unhealthy, 20 - 70 years n = 10 Health Status: unhealthy Condition: COVID-19 Age Group: 20 - 70 years Sex: M+F Population Size: 10 Sources: |
Arthralgia | 1 patient | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Abdominal pain | 2 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Anemia | 2 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Back pain | 2 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Edema peripheral | 2 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Gastroesophageal reflux disease | 2 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Stomach discomfort | 2 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Vomiting | 2 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Abdominal pain upper | 3 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Headache | 3 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Hypertension | 3 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Constipation | 4 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Diarrhea | 5 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Dyspepsia | 5 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Nausea | 6 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 6.0 |
weak | likely (co-administration study) Comment: may lead to substantial increases in blood concentrations of tizanidine, a CYP1A2 substrate; can't find inhibition value Page: 6.0 |
||
yes [IC50 114 uM] | ||||
yes [IC50 28 uM] | ||||
yes [IC50 6.7 uM] | ||||
Page: 1.0 |
yes [Inhibition 100 uM] | |||
Page: 1.0 |
yes [Inhibition 100 uM] | |||
Page: 1.0 |
yes [Inhibition 100 uM] | |||
yes [Ki 0.6 uM] | ||||
yes [Ki 9.7 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
The effect of rabeprazole alone or in combination with H2 receptor blocker on intragastric pH: a pilot study. | 2004 Dec |
|
Switching of H(2)-Receptor Antagonists to Over-the-Counter Status in Finland : Implications for Consumption and Adverse Effects. | 2005 |
|
[Gastroprotective effects of histamine H2-receptor blockers in Helicobacter-like gastric mucosa lesions]. | 2005 |
|
Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes. | 2005 Apr |
|
Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). | 2005 Dec |
|
Effect of pre-operative short course famotidine on tumor infiltrating lymphocytes in colorectal cancer: a double blind, placebo controlled, prospective randomized study. | 2005 Dec |
|
Synergistic action of famotidine and chlorpheniramine on acetic acid-induced chronic gastric ulcer in rats. | 2005 Dec 7 |
|
Comparative study of the speed of acid-suppressing effects of oral administration of cimetidine and famotidine. | 2005 Jul |
|
Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status. | 2005 Jul 1 |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
A prospective randomized trial of either famotidine or omeprazole for the prevention of bleeding after endoscopic mucosal resection and the healing of endoscopic mucosal resection-induced ulceration. | 2005 Jun |
|
Comparison of hemostatic effects by route of H2 receptor antagonist administration following endoscopic mucosal resection in patients with neoplastic gastric lesions. | 2005 Jun |
|
Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine. | 2005 Jun |
|
New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline. | 2005 Jun |
|
Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies. | 2005 Jun |
|
Randomized, double-blind, placebo-controlled crossover trial of famotidine in patients with functional dyspepsia. | 2005 Jun |
|
Alteration of intracellular histamine H2 receptor cycling precedes antagonist-induced upregulation. | 2005 Nov |
|
A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. | 2005 Oct |
|
Effect of preoperative short course famotidine on TILs and survival in breast cancer. | 2005 Oct-Dec |
|
Histamine mediates the stimulatory action of ghrelin on acid secretion in rat stomach. | 2006 Aug |
|
Assessing the efficacy of famotidine and rebamipide in the treatment of gastric mucosal lesions in patients receiving long-term NSAID therapy (FORCE--famotidine or rebamipide in comparison by endoscopy). | 2006 Dec |
|
Attenuation of acid induced oesophagitis in VR-1 deficient mice. | 2006 Jan |
|
Coagulation-dependent gene expression and liver injury in rats given lipopolysaccharide with ranitidine but not with famotidine. | 2006 May |
|
Tolerance to H2 receptor antagonist correlates well with the decline in efficacy against gastroesophageal reflux in patients with gastroesophageal reflux disease. | 2006 Oct |
|
Expression of HSP72 in the gastric mucosa is regulated by gastric acid in rats-correlation of HSP72 expression with mucosal protection. | 2006 Oct 20 |
|
Omeprazole may be superior to famotidine in the management of iatrogenic ulcer after endoscopic mucosal resection: a prospective randomized controlled trial. | 2006 Sep 1 |
|
[Clinical study on effect of Jianwei Yuyang Granule in treating patients with gastric ulcer]. | 2007 Jul |
|
Novel role of famotidine in downregulation of matrix metalloproteinase-9 during protection of ethanol-induced acute gastric ulcer. | 2007 Jul 15 |
|
The role of tumor necrosis factor alpha in lipopolysaccharide/ranitidine-induced inflammatory liver injury. | 2007 Nov |
|
A randomized, double-blind, placebo-controlled clinical study of the histamine H2-receptor antagonist famotidine in Japanese patients with nonerosive reflux disease. | 2008 |
|
Can negative cardiac effect of proton pump inhibitor and high-dose H2-blocker have clinical influence on patients with stable angina? | 2008 Aug |
|
Antinociception induced by central administration of histamine in the formalin test in rats. | 2008 Jul-Sep |
|
High-dose intensity pulse interleukin-2 with famotidine has activity in metastatic melanoma. | 2008 Oct |
|
[Efficacy and safety of famotidine for the treatment of stress ulcers in neonates]. | 2008 Oct |
|
Gastroprotective and anti-oxidative properties of ascorbic acid on indomethacin-induced gastric injuries in rats. | 2008 Winter |
|
Risk factors for the development of gastric mucosal lesions in rheumatoid arthritis patients receiving long-term nonsteroidal anti-inflammatory drug therapy and the efficacy of famotidine obtained from the FORCE study. | 2009 |
|
Comparison of the effects of omeprazole and famotidine in treatment of upper abdominal symptoms in patients with reflux esophagitis. | 2009 |
|
High-dose intensity pulse interleukin-2 with famotidine in metastatic kidney cancer. | 2009 Apr |
|
Phosphodiesterase isozymes involved in regulating acid secretion in the isolated mouse stomach. | 2009 Dec |
|
Activity of continuous infusion + pulse interleukin-2 with famotidine in metastatic melanoma. | 2009 Feb |
|
Comparative study on the gastroprotective potential of some antidepressants in indomethacin-induced ulcer in rats. | 2009 Jul 15 |
|
Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). | 2009 Jun |
|
Characterization of mechanisms underlying the effects of esomeprazole on the impairment of gastric ulcer healing with addition of NSAID treatment. | 2009 Jun |
|
Effects of pantoprazole on ulcer healing delay associated with NSAID treatment. | 2009 Mar |
|
[Neurological complications of acute intermittent porphyria precipitated by porphyrinogenic drugs and efficiency of heme-arginate treatment]. | 2009 Sep |
|
Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma. | 2010 Apr |
|
Rebamipide may be comparable to H2 receptor antagonist in healing iatrogenic gastric ulcers created by endoscopic mucosal resection: a prospective randomized pilot study. | 2010 Apr |
|
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. | 2010 Jan |
|
Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease. | 2010 Jul 30 |
|
Hepatoprotective, antinociceptive and antioxidant activities of cimetidine, ranitidine and famotidine as histamine H2 receptor antagonists. | 2011 Feb |
Patents
Sample Use Guides
The recommended adult oral dosage for active duodenal ulcer is 40 mg once a day at bedtime. Most patients heal within 4 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23857299
Famotidine (10-1,000 µM) inhibited methadone and oxycodone cytochrome P450-dependent metabolism >50%.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 23:21:05 UTC 2023
by
admin
on
Wed Jul 05 23:21:05 UTC 2023
|
Record UNII |
5QZO15J2Z8
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
A02BA03
Created by
admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
|
||
|
NDF-RT |
N0000175784
Created by
admin on Wed Jul 05 23:21:06 UTC 2023 , Edited by admin on Wed Jul 05 23:21:06 UTC 2023
|
||
|
WHO-VATC |
QA02BA03
Created by
admin on Wed Jul 05 23:21:06 UTC 2023 , Edited by admin on Wed Jul 05 23:21:06 UTC 2023
|
||
|
NCI_THESAURUS |
C29702
Created by
admin on Wed Jul 05 23:21:06 UTC 2023 , Edited by admin on Wed Jul 05 23:21:06 UTC 2023
|
||
|
WHO-ATC |
A02BA53
Created by
admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
|
||
|
LIVERTOX |
NBK548228
Created by
admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
|
||
|
WHO-VATC |
QA02BA53
Created by
admin on Wed Jul 05 23:21:06 UTC 2023 , Edited by admin on Wed Jul 05 23:21:06 UTC 2023
|
||
|
NDF-RT |
N0000000151
Created by
admin on Wed Jul 05 23:21:06 UTC 2023 , Edited by admin on Wed Jul 05 23:21:06 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Famotidine
Created by
admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
|
PRIMARY | |||
|
DTXSID5023039
Created by
admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
|
PRIMARY | |||
|
DB00927
Created by
admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
|
PRIMARY | |||
|
757810
Created by
admin on Wed Jul 05 23:21:06 UTC 2023 , Edited by admin on Wed Jul 05 23:21:06 UTC 2023
|
PRIMARY | |||
|
D015738
Created by
admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
|
PRIMARY | |||
|
SUB07503MIG
Created by
admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
|
PRIMARY | |||
|
5QZO15J2Z8
Created by
admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
|
PRIMARY | |||
|
5217
Created by
admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
|
PRIMARY | |||
|
100000092363
Created by
admin on Wed Jul 05 23:21:06 UTC 2023 , Edited by admin on Wed Jul 05 23:21:06 UTC 2023
|
PRIMARY | |||
|
7074
Created by
admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
|
PRIMARY | |||
|
3325
Created by
admin on Wed Jul 05 23:21:06 UTC 2023 , Edited by admin on Wed Jul 05 23:21:06 UTC 2023
|
PRIMARY | |||
|
M5241
Created by
admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL902
Created by
admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
|
PRIMARY | |||
|
4278
Created by
admin on Wed Jul 05 23:21:06 UTC 2023 , Edited by admin on Wed Jul 05 23:21:06 UTC 2023
|
PRIMARY | RxNorm | ||
|
FAMOTIDINE
Created by
admin on Wed Jul 05 23:21:06 UTC 2023 , Edited by admin on Wed Jul 05 23:21:06 UTC 2023
|
PRIMARY | |||
|
1269200
Created by
admin on Wed Jul 05 23:21:06 UTC 2023 , Edited by admin on Wed Jul 05 23:21:06 UTC 2023
|
PRIMARY | |||
|
4975
Created by
admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
|
PRIMARY | |||
|
1129
Created by
admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
|
PRIMARY | |||
|
W-33
Created by
admin on Wed Jul 05 23:21:06 UTC 2023 , Edited by admin on Wed Jul 05 23:21:06 UTC 2023
|
PRIMARY | |||
|
3572
Created by
admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
|
PRIMARY | |||
|
C29045
Created by
admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
|
PRIMARY | |||
|
5QZO15J2Z8
Created by
admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
|
PRIMARY | |||
|
76824-35-6
Created by
admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
USP
|
||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
EXCRETED UNCHANGED |
Following IV administration
URINE
|
||
|
TARGET->INVERSE AGONIST |
The mean minimum daily requirement of famotidine to control gastric acid hypersecretion was 0.24 g (range 0.08–0.48 g) compared with 2.1 g (range 0.6–3.6 g) for ranitidine and 7.8 g (range 1.2–13.2 g) for cimetidine. is nine times more potent than ranitidine and 32 times more potent than cimetidine, has a longer duration of action than ranitidine or cimetidine,
|
||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
TRANSPORTER -> SUBSTRATE |
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET->INVERSE AGONIST |
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> NON-INHIBITOR |
IC50
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
TRANSPORTER -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 2.5
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.9
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 0.19
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||